CN109789094A - κ-阿片类受体激动剂的持续释放组合物 - Google Patents

κ-阿片类受体激动剂的持续释放组合物 Download PDF

Info

Publication number
CN109789094A
CN109789094A CN201780045316.4A CN201780045316A CN109789094A CN 109789094 A CN109789094 A CN 109789094A CN 201780045316 A CN201780045316 A CN 201780045316A CN 109789094 A CN109789094 A CN 109789094A
Authority
CN
China
Prior art keywords
substituted
release composition
pain
sustained release
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780045316.4A
Other languages
English (en)
Chinese (zh)
Inventor
高塔姆·加特内卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Titan Pharmaceuticals Inc
Original Assignee
Jt Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jt Pharmaceutical Co filed Critical Jt Pharmaceutical Co
Publication of CN109789094A publication Critical patent/CN109789094A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201780045316.4A 2016-06-03 2017-06-05 κ-阿片类受体激动剂的持续释放组合物 Pending CN109789094A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345583P 2016-06-03 2016-06-03
US62/345,583 2016-06-03
PCT/US2017/035874 WO2017210668A1 (en) 2016-06-03 2017-06-05 Sustained release compositions of kappa-opioid receptor agonist

Publications (1)

Publication Number Publication Date
CN109789094A true CN109789094A (zh) 2019-05-21

Family

ID=60478002

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780045316.4A Pending CN109789094A (zh) 2016-06-03 2017-06-05 κ-阿片类受体激动剂的持续释放组合物

Country Status (5)

Country Link
US (1) US20200316159A1 (enExample)
EP (1) EP3463306A4 (enExample)
JP (1) JP2019517586A (enExample)
CN (1) CN109789094A (enExample)
WO (1) WO2017210668A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114873741A (zh) * 2022-05-31 2022-08-09 南京大学 一种脱氮缓释碳源材料及其制备方法和应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
AU2019275406B2 (en) 2018-05-24 2024-11-14 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2021026492A1 (en) 2019-08-07 2021-02-11 Humanwell Pharmaceutical US Kappa opioid receptor peptide amide agonists
AU2021236662A1 (en) * 2020-03-18 2022-11-10 Cara Therapeutics, Inc. Oligosaccharide formulations of kappa opioid receptor agonists
AU2020454871A1 (en) 2020-06-25 2023-01-19 Humanwell Pharmaceutical US Peptides for treatment of medical disorders
US20240226226A1 (en) * 2021-04-14 2024-07-11 Titan Pharmaceuticals, Inc. Kappa-opioid receptor agonist implants for treatment of pruritus
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140171457A1 (en) * 2002-05-31 2014-06-19 Titan Pharmaceuticals, Inc. Implantable Polymeric Device for Sustained Release of Buprenorphine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009538310A (ja) * 2006-05-26 2009-11-05 カラ セラピューティクス インコーポレイテッド 哺乳動物におけるプロラクチンを上昇させる方法
US7842662B2 (en) * 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
CA2667155C (en) * 2006-11-10 2016-05-10 Cara Therapeutics, Inc. Synthetic peptide amides
JP5877640B2 (ja) * 2007-05-01 2016-03-08 フンダサオ・デ・アムパロ・ア・ペスキーサ・ド・エスタド・デ・サン・パウロ−エフイ・ア・ペー・エ・エシ・ペー 鎮痛化合物
KR20130097201A (ko) * 2010-09-02 2013-09-02 그뤼넨탈 게엠베하 음이온성 중합체를 포함하는 내변조성 투여형
EP3287172A1 (en) * 2012-12-06 2018-02-28 Stealth Peptides International, Inc. Combinations of peptide therapeutics and methods for using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140171457A1 (en) * 2002-05-31 2014-06-19 Titan Pharmaceuticals, Inc. Implantable Polymeric Device for Sustained Release of Buprenorphine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRANCIS M.HUGHES ET AL.: "Development of a Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonist Targeting Peripheral Pain", 《THE OPEN MEDICINAL CHEMISTRY JOURNAL》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114873741A (zh) * 2022-05-31 2022-08-09 南京大学 一种脱氮缓释碳源材料及其制备方法和应用

Also Published As

Publication number Publication date
EP3463306A4 (en) 2020-03-11
WO2017210668A1 (en) 2017-12-07
JP2019517586A (ja) 2019-06-24
US20200316159A1 (en) 2020-10-08
EP3463306A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
CN109789094A (zh) κ-阿片类受体激动剂的持续释放组合物
JP6608309B2 (ja) Ｃｍｔ及び関連疾患の処置のための新規な治療的アプローチ
ES2690061T3 (es) Composiciones para tratar la enfermedad de Parkinson
KR20140041457A (ko) 신경 장애 치료용 신규 조성물
JP2012528818A (ja) Ｃｍｔ及び関連障害を処置するための新たな組成物
EA023380B1 (ru) Комбинация пилокарпина и метимазола для лечения заболевания шарко-мари-тута и связанных с ним нарушений
JP5757544B2 (ja) 癌治療に用いられるベムラフェニブとインターフェロンを含む併用療法
ES2773834T3 (es) Métodos y composiciones para tratar la depresión usando ciclobenzaprina
TW201636024A (zh) 阿吡莫德組成物及其使用方法
US9050275B2 (en) Methods of screening for and treating autism spectrum disorders and compositions for same
CN114173578A (zh) 用于治疗癌症的组合物和方法
US20240358791A1 (en) Peptides and methods of treating dystrophy-related disorders using the same
JP6180417B2 (ja) 心不全またはニューロン損傷の治療剤製造のための化合物の使用
CN109069450A (zh) 神经障碍的新的组合疗法
CN102046163A (zh) 使用乌地那非(udenafil)与阿呋唑嗪(alfuzosin)或奥昔布宁(oxybutynin)组合治疗膀胱过度活动症
Pustovit et al. Muscarinic receptor 1 allosteric modulators stimulate colorectal emptying in dog, mouse and rat and resolve constipation
US9176146B2 (en) Methods of treating autism spectrum disorders and compositions for same
AU2008334933B2 (en) Method and composition for treating a serotonin receptor-mediated condition
EP1845984B1 (en) Methylphenidate derivatives and uses of them
EP2710893A1 (en) Methods of treating autism spectrum disorders and compositions for same
EP4066850A2 (en) Peptides and methods of treating dystrophy-related disorders using the same
CN101411700B (zh) 5,7,4'-三羟基二氢黄酮或其衍生物用于止痛的用途
CN119745887A (zh) 小分子激动剂tepp-46在制备预防和/或治疗主动脉瘤及相关心血管疾病的药物中的应用
US20120136005A1 (en) Eltoprazine for the treatment of anxiety
AU2015275276A1 (en) Method and composition for treating a serotonin receptor-mediated condition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210531

Address after: California, USA

Applicant after: TITAN PHARMACEUTICALS, Inc.

Address before: south carolina

Applicant before: JT Pharmaceuticals, Inc.

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20190521

RJ01 Rejection of invention patent application after publication